Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic solutions for the treatment
Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for
19 million euros received for the sale of its building locate in Lyon and the concomitant signature of a 12-year renewable lease 25.3 million cash position as of March 31, 2022 Significant
Number of Shares and Voting Rights of ADOCIA as of April 30th, 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.